Therapy Insight: Pyoderma gangrenosum - Old disease, new management

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 12, 2005, Pages 587-594

  Campbell, Simon ^a   Cripps, Sarah ^a   Jewell, Derek P ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Neutrophilic dermatoses; Pyoderma gangrenosum; Therapy; Ulcerative colitis

Indexed keywords

ALPHA2A INTERFERON; AMOXICILLIN; ANTIBIOTIC AGENT; AZATHIOPRINE; CEFUROXIME; CLOFAZIMINE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RIFAMPICIN; STEROID; TETRACYCLINE; THALIDOMIDE; TRIAMCINOLONE HEXACETONIDE; TSUKUBAENOLIDE; VANCOMYCIN; DERMATOLOGICAL AGENT; GLUCOCORTICOID; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; APHERESIS; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG ABSORPTION; DRUG EFFICACY; DRY SKIN; ENTERITIS; EVIDENCE BASED MEDICINE; HEMOLYSIS; HIRSUTISM; HUMAN; HYPERPIGMENTATION; HYPERTENSION; ISCHEMIA; LIVER TOXICITY; LYMPHOPROLIFERATIVE DISEASE; MEDICAL SPECIALIST; MESENTERY; METHEMOGLOBINEMIA; MICROBIOLOGY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PANCREATITIS; PLASMAPHERESIS; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REVIEW; SENSORIMOTOR NEUROPATHY; SEPSIS; SKIN BIOPSY; SKIN DISCOLORATION; STEROID THERAPY; TERATOGENICITY; TREMOR; WOUND CARE; WOUND DRESSING; WOUND INFECTION; DRUG ANTAGONISM; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BLOOD COMPONENT REMOVAL; DERMATOLOGIC AGENTS; GLUCOCORTICOIDS; HUMANS; PRACTICE GUIDELINES; PYODERMA GANGRENOSUM; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644877705     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0339     Document Type: Review

References (51)

1. Brunsting LA et al. (1930) Pyoderma gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol 22: 655-680
2. Hughes AP et al. (2000) Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284: 1546-1548
3. Levitt MD et al. (1991) Pyoderma gangrenosum in inflammatory bowel disease. Br J Surg 78: 676-678
4. Adachi Y et al. (1998) Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol 111: 259-268
5. Schofer H and Baur S (2002) Successful treatment of postoperative pyoderma gangrenosum with cyclosporin. J Eur Acad Dermatol Venereol 16: 148-151
6. Weichert G and Sauder DN (1998) Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. J Am Acad Dermatol 39: 648-650
7. Friedman S et al. (2001) Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 7: 1-7
8. Powell FC et al. (1985) Pyoderma gangrenosum: A review of 86 patients. Q J Med 55: 173-186
9. Powell FC et al. (1996) Pyoderma gangrenosum: Classification and management. J Am Acad Dermatol 34: 395-409
10. Bernstein CN et al. (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 96: 1116-1122
11. Callen JP (1998) Pyoderma gangrenosum. Lancet 351: 581-585
12. Orchard T (2003) Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep 5: 512-517
13. von den Driesch P (1997) Pyoderma gangrenosum: A report of 44 cases with follow-up. Br J Dermatol 137: 1000-1005
14. Sams HH et al. (2003) Crohn's disease of the penis masquerading as pyoderma gangrenosum: A case report and review of the literature. Cutis 72: 432-437
15. Snyder RA (1986) Pyoderma gangrenosum involving the head and neck. Arch Dermatol 122: 295-302
16. Wayte JA et al. (1995) Pyoderma gangrenosum, erythema elevatum diutinum and IgA monoclonal gammopathy. Australas J Dermatol 36: 21-23
17. Beele H et al. (2000) Pyoderma gangrenosum as an early revelator of acute leukaemia. Dermatology 200: 176-178
18. Bader U et al. (2000) Leg ulcers in patients with myeloproliferative disorders: Disease- or treatment-related? Dermatology 200: 45-48
19. Goulden V et al. (1994) Pyoderma gangrenosum associated with paroxysmal nocturnal haemoglobinuria. Clin Exp Dermatol 19: 271-273
20. Kanel KT et al. (1987) Pyoderma gangrenosum with myelofibrosis. Am J Med 82: 1031-1034
21. Brooklyn TN et al. (2005) Infliximab for the treatment of pyoderma gangrenosum: A randomised, double-blind placebo-controlled trial [abstract]. Gut 54 (Suppl 2): A23
22. Lyon CC et al. (2000) Parastomal pyoderma gangrenosum: Clinical features and management. J Am Acad Dermatol 42: 992-1002
23. Goldstein F et al. (1985) Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 7: 499-501
24. Lyon CC et al. (2001) Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat 12: 13-17
25. Wenzel J et al. (2002) Topical treatment of pyoderma gangrenosum. Dermatology 205: 221-223
26. Breathnach SM et al. (1981) Idiopathic pyoderma gangrenosum and impaired lymphocyte function: Failure of azathioprine and corticosteroid therapy. Br J Dermatol 104: 567-573
27. Teitel AD (1996) Treatment of pyoderma gangrenosum with methotrexate. Cutis 57: 326-328
28. Carp JM et al. (1997) Intravenous cyclosporine therapy in the treatment of pyoderma gangrenosum secondary to Crohn's disease. Cutis 60: 135-138
29. Lim KK et al. (1996) Cyclosporine in the treatment of dermatologic disease: An update. Mayo Clin Proc 71: 1182-1191
30. Grange F et al. (2002) Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: Rapid cure with infliximab. Dermatology 205: 278-280
31. Jenne L et al. (2004) Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol 150: 380-382
32. Mimouni D et al. (2003) Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 148: 813-816
33. Galun E et al. (1986) Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 81: 988-989
34. Obasi OE (1991) Pyoderma gangrenosum and malignant pyoderma in Nigeria. Clin Exp Dermatol 16: 34-37
35. Kang S and Dover JS (1990) Successful treatment of eruptive pyoderma gangrenosum with intravenous vancomycin and mezlocillin. Br J Dermatol 123: 389-393
36. Kaneko T et al. (2003) Superficial granulomatous pyoderma: A case report of two Japanese patients and clinical comparison with foreign patients. J Dermatol 30: 472-476
37. Farrell AM et al. (1998) Pyoderma gangrenosum of the penis. Br J Dermatol 138: 337-340
38. Miralles ES et al. (1994) Minocycline hydrochloride hyperpigmentation complicating treatment of pyoderma gangrenosum. J Dermatol 21: 965-967
39. Moraes M and Russo G (2001) Thalidomide and its dermatologic uses. Am J Med Sci 321: 321-326
40. Chaudhry V et al. (2002) Thalidomide-induced neuropathy. Neurology 59: 1872-1875
41. Ohmori T et al. (2003) Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 98: 2101-2102
42. Kanekura T et al. (2002) Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 47: 320-321
43. Biswas P et al. (2003) In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: Implications for treatment of HIV infection and other immune disorders. Clin Immunol 109: 355-358
44. Kontochristopoulos GJ et al. (2004) Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology 209: 233-236
45. Rampal P et al. (1998) Colchicine in pyoderma gangrenosum. Lancet 351: 1134-1135
46. Bulvik S and Jacobs P (1997) Pyoderma gangrenosum in myelodysplasia responding to granulocyte-macrophage colony stimulating factor (GM-CSF). Br J Dermatol 136: 637-638
47. Sanchez RJ et al. (1995) The treatment of cyclosporine A-resistant pyoderma gangrenosum with recombinant interferon alfa-2. Med Clin (Barc) 104: 517-518
48. Kaminska R et al. (1999) Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol 24: 81-85
49. Daniels NH and Callen JP (2004) Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol 140: 1427-1429
50. Lee MR and Cooper AJ (2004) Mycophenolate mofetil in pyoderma gangrenosum. J Dermatolog Treat 15: 303-307
51. Reichrath J et al. (2005) Treatment recommendations for pyoderma gangrenosum: An evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 53: 273-283